Boston Advisors LLC boosted its stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 0.7% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 36,190 shares of the biopharmaceutical company’s stock after buying an additional 245 shares during the period. Boston Advisors LLC’s holdings in Vanda Pharmaceuticals were worth $405,000 at the end of the most recent quarter.
Other institutional investors have also recently bought and sold shares of the company. Bank of Montreal Can purchased a new position in Vanda Pharmaceuticals during the second quarter valued at approximately $132,000. Acadian Asset Management LLC boosted its stake in Vanda Pharmaceuticals by 1,243.1% in the second quarter. Acadian Asset Management LLC now owns 149,689 shares of the biopharmaceutical company’s stock worth $1,675,000 after buying an additional 138,544 shares during the period. BNP Paribas Arbitrage SA boosted its stake in Vanda Pharmaceuticals by 3.4% in the second quarter. BNP Paribas Arbitrage SA now owns 43,511 shares of the biopharmaceutical company’s stock worth $487,000 after buying an additional 1,411 shares during the period. Amici Capital LLC bought a new stake in Vanda Pharmaceuticals during the first quarter worth approximately $418,000. Finally, Sphera Funds Management LTD. boosted its stake in Vanda Pharmaceuticals by 10.8% in the first quarter. Sphera Funds Management LTD. now owns 512,051 shares of the biopharmaceutical company’s stock worth $4,281,000 after buying an additional 50,000 shares during the period. 86.06% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) traded up 3.57% during midday trading on Thursday, reaching $16.83. 1,134,731 shares of the company’s stock were exchanged. The firm has a 50 day moving average of $15.42 and a 200-day moving average of $11.49. The stock’s market cap is $728.47 million. Vanda Pharmaceuticals Inc. has a one year low of $6.91 and a one year high of $18.00.
Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its earnings results on Wednesday, July 27th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.23) by $0.12. Vanda Pharmaceuticals had a negative net margin of 31.85% and a negative return on equity of 22.51%. The business earned $36.02 million during the quarter, compared to the consensus estimate of $36.03 million. During the same quarter last year, the firm earned ($0.13) earnings per share. The business’s revenue for the quarter was up 30.6% on a year-over-year basis. On average, equities research analysts anticipate that Vanda Pharmaceuticals Inc. will post ($0.61) earnings per share for the current year.
A number of research firms recently commented on VNDA. Piper Jaffray Cos. set a $19.00 price target on shares of Vanda Pharmaceuticals and gave the stock a “buy” rating in a report on Saturday, October 1st. Jefferies Group began coverage on shares of Vanda Pharmaceuticals in a report on Thursday. They issued a “buy” rating on the stock. Brean Capital reaffirmed a “buy” rating and issued a $24.00 price target (up previously from $20.00) on shares of Vanda Pharmaceuticals in a report on Monday, August 29th. JMP Securities lifted their price target on shares of Vanda Pharmaceuticals from $18.00 to $22.00 and gave the stock a “market outperform” rating in a report on Friday, August 26th. Finally, Zacks Investment Research raised shares of Vanda Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $14.00 price target on the stock in a report on Tuesday, August 2nd. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Vanda Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $18.67.
In related news, insider James E. Flynn sold 547,886 shares of the firm’s stock in a transaction that occurred on Monday, September 19th. The shares were sold at an average price of $15.66, for a total transaction of $8,579,894.76. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider James E. Flynn sold 1,120,461 shares of the firm’s stock in a transaction that occurred on Friday, September 23rd. The shares were sold at an average price of $16.56, for a total transaction of $18,554,834.16. The disclosure for this sale can be found here. Corporate insiders own 8.45% of the company’s stock.
Vanda Pharmaceuticals Company Profile
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Company’s product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051.
Want to see what other hedge funds are holding VNDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vanda Pharmaceuticals Inc. (NASDAQ:VNDA).
Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.